Efficacy and safety of biphasic insulin aspart 70/30 in type 2 diabetes patients of different race or ethnicity (INITIATEplus trial)

Current Medical Research and Opinion

Volumn 28, Issue 7, 2012, Pages 1203-1211

  Trippe, Bruce S ^a   Shepherd, Mark D ^b   Coulter, Franklin C ^c   Bhargava, Anuj ^d   Brett, Jason ^e   Chu, Pei Ling ^e   Oyer, David S ^f,g  

^a Department of Endocrinology ^*  (United States)

^b Endocrinology Consultants   (United States)

^c Coulter Clinic ^*  (United States)

^d Iowa Diabetes and Endocrinology Center   (United States)

^e NOVO NORDISK INC   (United States)

^f Internal Medicine   (United States)

^g INITIATEplus Study Group   (United States)

Author keywords

BIAsp 30; Biphasic insulin aspart 70 30; Ethnicity; Glucose control; INITIATEplus; NovoLog Mix 70 30; Race; Self titration; Type 2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN ASPART;

AFRICAN AMERICAN; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; ETHNICITY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HISPANIC; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; TREATMENT DURATION;

AFRICAN AMERICANS; BIPHASIC INSULINS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN ASPART; INSULIN, ISOPHANE; MALE; MIDDLE AGED; UNITED STATES;

EID: 84863616307     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2012.686444     Document Type: Article

References (26)

1. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86
2. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
3. Writing Team for the DCCT/EDIC Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002;287:2563-9
4. American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care 2012;35(Suppl1):S11-63
5. Handelsman Y, Mechanick JI, Blonde L, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract 2011;17(Suppl2):1-53
6. NovoLog Mix 70/30 (70 insulin aspart protamine suspension and 30 insulin aspart injection, rDNA origin) [prescribing information]. Novo Nordisk: Princeton, NJ, September 2011
7. Oyer DS, Shepherd MD, Coulter FC, et al. A1c control in a primary care setting: self-titrating an insulin analog pre-mix (INITIATEplus trial). Am J Med 2009;122:1043-9
8. Boehm BO, Home PD, Behrend C, et al. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients. Diabet Med 2002;19:393-9 (Pubitemid 34534214)
9. Garber AJ, Wahlen J, Wahl T, et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (the 1-2-3 study). Diabetes Obes Metab 2006;8:58-66
10. Raskin P, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005;28:260-5 (Pubitemid 40170923)
11. Maggs D, Shen L, Strobel S, et al. Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: a pooled post hoc analysis. Metabolism 2003;52:1638-42 (Pubitemid 38049286)
12. Arslanian S, Suprasongsin C, Janosky JE. Insulin secretion and sensitivity in black versus white prepubertal healthy children. J Clin Endocrinol Metab 1997;82:1923-7 (Pubitemid 127495211)
13. Arslanian SA, Saad R, Lewy V, et al. Hyperinsulinemia in African-American children: decreased insulin clearance and increased insulin secretion and its relationship to insulin sensitivity. Diabetes 2002;51:3014-19
14. Osei K, Cottrell DA, Harris B. Differences in basal and poststimulation glucose homeostasis in nondiabetic first degree relatives of black and white patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 1992;75:82-6
15. Herman WH, Ma Y, Uwaifo G, et al. Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program. Diabetes Care 2007;30:2453-7 (Pubitemid 47547771)
16. Herman WH, Dungan KM, Wolffenbuttel BH, et al. Racial and ethnic differences in mean plasma glucose, A1C, and 1,5-anhydroglucitol in over 2000 patients with type 2 diabetes. J Clin Endocrinol Metab 2009;94:1689-94
17. Cook CB, Ziemer DC, El-Kebbi IM, et al. Diabetes in urban African-Americans. XVI. Overcoming clinical inertia improves glycemic control in patients with type 2 diabetes. Diabetes Care 1999;22:1494-500 (Pubitemid 29418245)
18. Heisler M, Faul JD, Hayward RA, et al. Mechanisms for racial and ethnic disparities in glycemic control in middle-aged and older Americans in the Health and Retirement Study. Arch Intern Med 2007;167:1853-60 (Pubitemid 47481480)
19. Brown AF, Gregg EW, Stevens MR, et al. Race, ethnicity, socioeconomic position, and quality of care for adults with diabetes enrolled in managed care: the Translating Research Into Action for Diabetes (TRIAD) study. Diabetes Care 2005;28:2864-70 (Pubitemid 43942916)
20. Karter AJ, Ferrara A, Darbinian JA, et al. Self-monitoring of blood glucose: language and financial barriers in a managed care population with diabetes. Diabetes Care 2000;23:477-83 (Pubitemid 30185790)
21. Bleyer AJ, Hire D, Russell GB, et al. Ethnic variation in the correlation between random serum glucose concentration and glycated haemoglobin. Diabet Med 2009;26:128-33
22. Christiansen JS, Liebl A, Davidson JA, et al. Mid-and high-ratio premix insulin analogues: potential treatment options for patients with type 2 diabetes in need of greater postprandial blood glucose control. Diabetes Obes Metab 2010;12:105-14
23. Wenying Y, Benroubi M, Borzi V, et al. Improved glycaemic control with BIAsp 30 in insulin-naive type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study. Curr Med Res Opin 2009;25:2643-54
24. Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716-30 (Pubitemid 350005153)
25. Almustafa M, Yeo JP, Khutsoane D. Glycaemic control and hypoglycaemia in the PRESENT study. Diabetes Res Clin Pract 2008;81(Suppl1):S10-15
26. Ligthelm RJ. Self-titration of biphasic insulin aspart 30/70 improves glycaemic control and allows easy intensification in a Dutch clinical practice. Prim Care Diabetes 2009;3:97-102